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Summary
Objective: To investigate the expression of a novel member of the mannose receptor family, Endo180 (also known as uPARAP), and the
distribution of Endo180 ligand(s) in the articular cartilage and growth plate of normal CBA mice and STR/ort mice, a well characterized model
of spontaneous osteoarthritis.
Design: A polyclonal anti-Endo180 antibody was used to determine receptor expression. The Endo180 extracellular domain fused to a
human immunoglobulin Fc tail was used to detect ligand.
Results: Endo180 receptor was strongly expressed in chondrocytes both in vitro and throughout the articular cartilage of young CBA and
STR/ort mice. Expression decreased in older animals. In STR/ort mice with osteoarthritic lesions, no upregulation of Endo180 was detected.
In the developing growth plate, Endo180 was expressed strongly by the proliferating chondrocytes. In contrast, Endo180 ligand was detected
most strongly in hypertrophic zone of the growth plate and only at low levels in articular cartilage. In cultured chondrocytes, Endo180 was
localized on the cell surface and in intracellular vesicles.
Conclusion: Constitutively recycling endocytic receptors function to internalize ligand from the extracellular milieu and the ability of Endo180
to bind both glycosylated ligands and collagens suggests a role in extracellular matrix remodeling. Expression of Endo180 in articular
cartilage chondrocytes of young, but not old, mice and the reciprocal expression of Endo180 and its ligands in the growth plate suggest that
this receptor is involved in cartilage development but not in cartilage homeostasis. In addition, our data indicates that Endo180 does not
appear to play a role in the development or progression of murine osteoarthritis.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Endo180 has recently been identified as the 4th and final
member of the mannose receptor family1. Structurally
these four type I transmembrane proteins (mannose recep-
tor, M-type phospholipase A2 receptor, DEC-205, Endo180)
have a common organization with an N-terminal cysteine-
rich domain followed by a fibronectin type II domain, eight
(ten in the case of DEC-205) C-type lectin-like domains
(CTLDs), a single pass transmembrane domain and a short
cytoplasmic domain (Fig. 1A). Like all members of the
mannose receptor family1, Endo180 is a constitutively
recycling endocytic receptor such that at any one time,
approximately 10–30% of the receptor can be detected on
the plasma membrane clustered into clathrin coated pits
and 70–90% is found in intracellular endosomes2,3. This
recycling property is characteristic of receptors which func-
tion to bind and internalize ligands for delivery to the low pH
intracellular compartments and to date, three ligand binding
activities have been identified for Endo180. First, Endo180
is a functional lectin with Ca2+-dependent binding to man-
nose, N-acetylglucosamine and fucose, and this activity is
mediated by CTLD24. Second, Endo180 is a collagen
binding/internalization receptor. Located towards the
N-terminus of Endo180 is a fibronectin type II domain which
shows strong sequence conservation between members of
the mannose receptor family and with homologous
collagen/gelatin domains in fibronectin and matrix
metalloproteinase-2 and -91. Moreover, soluble Endo180
constructs have been demonstrated to bind to both gelatin
and collagens I, II, IV and V and to native collagens in
tissue sections5 and cells expressing an Endo180 mutant
missing the fibronectin type II domain are defective in their
ability to bind and internalize collagens6,7. Third, Endo180
has been identified as part of a trimolecular complex with
urokinase-type plasminogen activator (uPA) and uPA
receptor (uPAR) – hence its alternative name, uPAR
associated protein (uPARAP)8. In addition to an important
role in proteolysis, binding of uPA to its receptor initiates a
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variety of intracellular cellular responses leading to
changes in cell adhesion and migration. However, as uPAR
is a GPI-anchored protein, accessory transmembrane
receptors such as Endo180 are required to mediate these
signalling events and/or the presentation of uPA/uPAR at
the cell surface9. Interestingly this association of uPAR and
Endo180 is blocked by collagens8 providing additional
evidence that Endo180 is a collagen receptor. Further clues
as to the function of Endo180 come from the demonstration
that Endo180 has a highly restricted cell type expression. In
particular, high levels of Endo180 transcripts have been
detected in neonatal chondrocytes at sites of active carti-
lage deposition10 and in embryonic tissues undergoing
primary ossification11. These data considered together sug-
gest a potential role for Endo180 in extracellular matrix
remodeling. Consequently it was of interest to determine
whether this receptor might play a role in the development
and maintenance of healthy cartilage and in clearing lig-
ands from extracellular matrices undergoing enhanced
metabolism, as in osteoarthritis.
Hyaline cartilages have an extensive extracellular matrix
that undergoes remodeling in the epiphyseal growth plate
cartilage during normal development and increased catab-
olism and attempts at repair in osteoarthritis in articular
cartilage. At least in the early stages of osteoarthritis, the
chondrocytes increase synthesis of proteoglycans and type
II collagen in an attempt to counteract the enhanced loss
of these molecules from the cartilage matrix12. Thus we
Fig. 1. Characterization of anti-Endo180 antibodies and soluble Endo180 constructs. (A) Diagram showing the domain structure of Endo180,
the soluble Endo180 (sEndo180) construct, and the soluble Endo180-Fc chimera (sEndo180-Fc). CR, cysteine-rich domain; FNII, fibronectin
type II domain; CTLD, C-type lectin-like domain. The signal sequence is not shown. COS-1 cells were transfected with pcDNA3 vector (-),
pcDNA3HindII-sEndo180 (sEndo180) or pIgplus-sEndo180-Fc (sEndo180-Fc), and the media harvested 5 days later. 20 µl of medium was
resolved by 10% non-reducing SDS-PAGE and blotted onto a nitrocellulose membrane. In parallel, 10 µg of lysate from MG63 cells which
express endogenous receptor (Endo180) was run and blotted. Membranes were incubated with anti-human Endo180 mAb A5/158 followed
by an HRP-conjugated anti-mouse Ig antibody, developed using the ECL reagent and exposed to film for 15 s. The increased molecular size
of the Fc construct results from dimerization via the Fc tail. (B) Serial cryosections of tibial articular cartilage from a 14-week STR/ort mouse
were probed with anti-Endo180 antibody that had been incubated with untreated nitrocellulose (- sEndo180) or preabsorbed with sEndo180
protein bound to nitrocellulose (+ sEndo180), followed by FITC-anti-rabbit Ig. Sections were viewed by fluorescence microscopy and
exposure settings were locked for qualitative analysis. AC, articular cartilage. Original magnification ×50.
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analysed the pattern of Endo180 receptor expression in
murine hyaline cartilages to test whether it is associated
with areas of normal remodeling or pathological break-
down. In parallel with these studies, we investigated the
expression and distribution of potential Endo180 ligand(s)
by probing sections with a soluble Endo180 extracellular
domain construct. Two inbred strains of mouse were used,
CBA (normal control) and STR/ort. The STR/ort mouse
develops a natural form of osteoarthritis in the tibial carti-
lage of the knee joint. In the Imperial College STR/ort
colony, 85% of male mice have osteoarthritic lesions in the
medial tibial articular cartilage by 35 weeks of age13. The
lateral tibial cartilage develops either less severe lesions or
is spared altogether. Thus Endo180 and Endo180 ligand
distribution were analysed in two key regions of extracellu-
lar matrix undergoing remodeling and turnover, the tibial
articular cartilage and the developing growth plate.
Methods
ANTIBODIES AND CONSTRUCTS
The pcDNA3HindIII-Endo180 construct3 was mutated
to insert a TAG stop codon at amino acid 1440. When
expressed this generates a soluble form of the Endo180
extracellular domain (sEndo180; Fig. 1). The pIgplus con-
struct encoding a sEndo180-Fc fusion protein is described
elsewhere14. Expression of these constructs in COS1 cells
was as previously described1. The sEndo180-Fc protein
was purified by protein G-Sepharose chromatography.
Peak fractions were pooled, dialysed into Hanks balanced
salt solution (InVitrogen, Paisley, U.K.) and aliquoted. The
integrity and purity of the final product was confirmed by
Western blotting with anti-Endo180 and anti-Fc antibodies
and by Coomassie-stained SDS-PAGE. The final yield of
protein was 75.6 µg at a concentration of 18.9 µg/ml. Puri-
fied intercellular cell adhesion molecule–1 (ICAM–1)-Fc
protein was provided by Dr H. Yarwood (Imperial College
London, U.K.).
The rabbit anti-Endo180 antibody and mouse anti-
human Endo180 monoclonal antibody A5/158 have been
previously described2,15. FITC-conjugated swine anti-rabbit
Ig was purchased from Dako (Ely, U.K.). FITC-conjugated
goat anti-human-Fc Ig was purchased from Serotec
(Kidlington, U.K.), HRP-anti-rabbit Ig was purchased from
Jackson Immunoresearch (West Grove, Pennsylvania),
Alexa 488 anti-rabbit Ig was purchased from Molecular
Probes (Eugene, Oregon). For preabsorption controls,
sEndo180 protein was resolved by 10% SDS-PAGE and
blotted onto nitrocellulose. The membrane was stained with
Ponceau S and the sEndo180 band excised. Polyclonal
anti-Endo180 antibody was incubated overnight at
4°C with either nitrocellulose containing sEndo180
(preabsorbed antibody) or with untreated nitrocellulose
(control antibody).
SECTIONING AND STAINING OF KNEE JOINTS
Male CBA and STR/ort mice aged between 5- and
35-weeks were killed by cervical dislocation. For each
analysis a minimum of three animals from each strain and
in each age group were used. The skin was removed from
the legs, the knee joints were dissected out with the
associated muscle, immersed in 5% aqueous polyvinyl
alcohol (PVA; GO4/Whacker Chemicals, Walton on
Thames, U.K.) for 10 min, cooled at −70°C in n-hexane
(BDH, Poole, U.K.), and then stored at −70°C. For section-
ing, joints were frozen onto metal chucks with 5% aqueous
PVA solution. Ten-micrometer sections were cut in the
anterior to posterior direction using a Bright’s cryostat fitted
with a bone cutting microtome and tungsten carbide-tipped
knife. Sections were flash-dried onto Superfrost Plus
microscope slides (BDH) and stored at −70oC.
For antibody staining, sections were thawed at room
temperature and fixed for 10 min in cold acetone. They
were then washed 3× at room temperature with PBS,
blocked with 10% swine serum (Dako) at 37°C for 30 min
and incubated with anti-Endo180 polyclonal antibody di-
luted 1:50 in PBS for 45 min at 37°C. Following incubation,
slides were washed 3× for 2 min with PBS, then incubated
with FITC-conjugated anti rabbit Ig, washed 3× for 2 min
with PBS and mounted in Vectashield PI (Vector Laborato-
ries, Burlingame, California) and photographed using an
Olympus Provis fluorescence microscope. To detect
Endo180 ligand distribution, sections were fixed as
described above, blocked with 10% goat serum (Dako)
at 37°C for 30 min and incubated with 18.9 µg/ml
sEndo180-Fc for 45 min at 37°C. Slides were then washed
3× for 2 min with PBS, incubated with FITC-conjugated anti
human-Fc antibody, washed 3× for 2 min with PBS and
mounted in Vectashield. In some cases, sections were
digested with protease free chondroitin ABC lyase (ICN
Biomedicals, Inc: 0.02 units per ml in 0.1 M Tris.HCl pH 8.0,
containing 30 mM sodium acetate) for 30 min at 37°C prior
to incubation with sEndo180-Fc.
CELL CULTURE
The MC615 murine chondrocyte cell line16 was cultured
in DME/HamsF12 (1:1) medium (InVitrogen) supplemented
with 10% fetal calf serum (FCS). The HT1080 fibrosarcoma
cell line and COS-1 cells were cultured in DME/10% FCS.
Immunofluorescence and FACS analysis was performed as
described previously3.
Results
EXPRESSION OF SOLUBLE ENDO180 CONSTRUCTS AND
SPECIFICITY OF THE ENDO180 ANTIBODY
Two types of soluble Endo180 constructs were used in
this study. First an untagged form in which a stop codon
had been inserted between CTLD8 and the transmem-
brane domain (sEndo180) and second, a chimeric con-
struct in which the Endo180 extracellular domain was fused
in frame with the Fc portion of human IgG (sEndo180-Fc)
(Fig. 1A). The presence of the Fc tail results in dimerization
(Fig. 1B) and enables efficient purification on a protein
G-column (see Methods) and detection using an anti-
human Fc antibody14. In separate studies we have demon-
strated that soluble constructs expressed in COS1 cells
retain their sugar4 and collagen5 binding properties. A
species cross-reactive rabbit anti-Endo180 antibody was
generated using purified human Endo180 protein as an
immunogen2. To assess the specificity of this antibody in
murine tissue sections, serial cryosections of tibial articular
cartilage from a 14-week STR/ort mouse were probed with
antibody preabsorbed with sEndo180 protein or with con-
trol antibody that had been preincubated with untreated
nitrocellulose (Fig. 1B). The latter showed strong staining of
the articular cartilage chondrocytes and this staining was
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indistinguishable from that obtained with untreated anti-
body (data not shown). In contrast, staining of articular
cartilage with the sEndo180 preabsorbed antibody was
reduced to background levels indicating the anti-Endo180
antibody recognises murine Endo180 and that the tissue
section staining observed is specific for the Endo180 pro-
tein (Fig. 1B). Similar immunofluorescence staining results
were obtained with cultured cells (data not shown).
EXPRESSION OF ENDO180 RECEPTOR AND LIGAND IN ARTICULAR
CARTILAGE
Cryostat sections cut through the joints of 5- to 35-week
CBA and STR/ort mice were examined for Endo180 recep-
tor expression. In young animals (5- to 6-weeks) of both
strains, Endo180 was detected in chondrocytes throughout
the whole depth of the medial articular cartilage (Fig. 2A,F).
This pattern of expression was retained in 9-week (Fig.
2B,G) and 14-week animals (Fig. 2C,H), although by the
older ages it was noticeable that staining was stronger in
the chondrocytes in the upper zone of the cartilage (see
also Fig. 1B). Although not quantitative, a small decrease in
staining in the STR/ort compared to the CBA mice was
noted. By 35-weeks, Endo180 staining in the articular
cartilage of both strains was much reduced and not signifi-
cantly above background levels (Fig. 2D,I). No staining was
observed with FITC anti-rabbit Ig alone (Fig. 2E,J). A similar
pattern of Endo180 immunostaining was seen in the lateral
tibial cartilage of both strains at each age (data not shown).
To determine whether the decreased staining in older
animals reflected a loss of Endo180 receptor or a reduction
in chondrocyte number, sections were counterstained with
propidium iodide to visualize cell nuclei (Fig. 3). In 14-week
mice, there was a strong correlation of Endo180 expression
and cell distribution although again, reduced Endo180
expression was observed in the chondrocytes in the deeper
zone of the medial articular cartilage (Fig. 3A,B). In ad-
dition, this image shows that chondrocytes in the femoral
cartilage are Endo180 positive. By 35 weeks, as previously
observed (Fig. 2), little Endo180 staining was observed in
Fig. 2. Endo180 expression in the medial tibial articular cartilage of CBA and STR/ort murine knee joint. Cryosections of tibial articular
cartilage of (A) 5-week, (B) 9-week, (C) 14-week, (D) 35-week CBA mice and (F) 6-week, (G) 9-week, (H) 14-week, (I) 35-week STR/ort mice
were probed with anti-Endo180 antibody followed by FITC-anti-rabbit Ig. (E, J) 5-week CBA and 6-week STR/ort mice probed with
FITC-anti-rabbit Ig alone, respectively. Sections were viewed by fluorescence microscopy and exposure settings were locked for qualitative
analysis. AC=articular cartilage, CT, calcified tissue. Original magnification ×50. Comparable results were obtained from a minimum of three
different animals at each age examined on at least two separate occasions.
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the medial articular cartilage despite cell nuclei being
clearly visualized with propidium iodide (Fig. 3C,D). Similar
results were obtained with equivalent sections from STR/
ort mice (data not shown). Additionally lateral articular
cartilage from both 35-week CBA (data not shown) and
STR/ort mice (Fig. 3E) again showed only background
levels of Endo180 expression demonstrating that decrease
in expression is not restricted to the medial cartilage.
In a large percentage of older STR/ort mice, osteoar-
thritic lesions develop in the medial tibial articular cartilage
(see17 where the range of STR/ort osteoarthritic lesions
and their grade are demonstrated). Development of such
lesions was not accompanied by upregulation of Endo180
expression (compare damaged 35-week medial cartilage
(Fig. 3F) with undamaged lateral cartilage from the
same joint (Fig. 3E) or undamaged medial cartilage from
an age-matched separate animal (Fig. 2I)). Similarly no
upregulation of Endo180 was observed in 24-week animals
showing evidence of osteoarthritic lesions (data not
shown).
To determine the expression of Endo180 ligand(s) in the
knee joint cartilage, sections were probed with protein G
purified sEndo180-Fc protein. Very little Endo180 ligand
was detected in the articular cartilage of young STR/ort
(Fig. 4A) or CBA (data not shown) mice at a time when
receptor expression was high (Fig. 4C). To ensure that this
lack of ligand staining did not reflect an intrinsic feature of
the articular cartilage, a cryosection from the same series
was probed, in parallel, with an ICAM-1-Fc fusion protein.
ICAM-1 is a ligand for the 22, M2, and X2 integrins.
As shown in Fig. 4B, ICAM-1-Fc binding is readily detect-
able on articular cartilage chondrocytes indicating that
these cells express 2 integrins and that soluble Fc
chimeras can be used successfully to probe for ligand
expression.
EXPRESSION OF ENDO180 RECEPTOR AND LIGAND(S) IN THE
EPIPHYSEAL GROWTH PLATE
In both young (5- to 6- week) CBA and STR/ort mice,
Endo180 receptor expression was detected strongly in the
proliferating, non-hypertrophic zone chondrocytes of the
epiphyseal growth plate (Fig. 5A,B). Expression decreased
gradually through the growth plate, with low levels in the
maturation zone and no detectable expression of Endo180
in the hypertrophic zone chondrocytes. In contrast to the
articular cartilage (Fig. 4) Endo180 ligand was detected
strongly in the epiphyseal growth plate of both CBA and
STR/ort mice (Fig. 5C-E). However, it was striking that
ligand distribution appeared to be a mirror image of recep-
tor expression. The former is predominantly found in the
hypertrophic zone of the epiphyseal cartilage whereas the
latter is predominantly expressed in the non-hypertrophic
proliferative zone. A possible explanation for lack of
Endo180 ligand staining in the proliferative zone of the
growth plate was the masking of sEndo180-Fc binding
sites. To address this, sections from 6-week STR/ort mice
were pretreated with chondroitinase prior to acetone fixa-
tion. Chondroitinase catalyses the depolymerization of
chondroitin sulphate side chains of proteoglycans and
Fig. 3. Loss of Endo180 expression in the articular cartilage from older animals. Cryosections through the tibial lateral articular cartilage of
(A, B) 14-week or (C, D) 35-week CBA mouse knee joints were probed with anti-Endo180 antibody followed by FITC-anti-rabbit Ig and
counterstained with propidium iodide. Sections were photographed independently in the FITC (A, C) and TRITC (B, D) channels. Sections
through the tibial lateral (E) and medial (F) articular cartilage from the same knee joint of a 35-week STR/ort mouse were probed with
anti-Endo180 antibody followed by FITC-anti-rabbit Ig. Arrows in panel F shows a grade 3 osteoarthritic lesion.17 AC, articular cartilage; CT,
calcified tissue; FC, femoral cartilage. Original magnification ×50.
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could therefore potentially aid the penetration of the
sEndo180-Fc probe into the cartilage matrix. However, no
detectable increase in staining was obtained (data not
shown). Similarly, no change in ligand staining was
observed after pretreating sections with proteinase K (data
not shown).
EXPRESSION OF ENDO180 BY CHONDROCYTES IN VITRO
The immunohistochemical studies indicate that Endo180
is expressed to a high level in chondrocytes in vivo. To
further investigate this, the expression and cellular distri-
bution of Endo180 was examined in a murine chondrocyte
cell line, MC61516. Since, Endo180 has previously been
reported to be expressed by fibroblast cells in culture2, the
HT1080 fibrosarcoma cell line was used as a control. As
expected FACS analysis of HT1080 cells revealed expres-
sion of Endo180 at the cell surface (Fig. 6A) while confocal
microscopy in both the horizontal and vertical planes dem-
onstrated a strong vesicular intracellular staining typical of
endosomes (Fig. 6B)3. An identical expression profile and
distribution was observed with the cultured MC615
chondrocytes indicating that in these cells Endo180
is a recycling receptor trafficking between the plasma
membrane and endosomal apparatus.
Discussion
Previous hybridization studies demonstrated high levels
of Endo180 expression in chondrogenic regions of the
mouse neonate10. Chondrogenic activity persists during
the growth of mammals, forming a template for the devel-
opment of the bony skeleton, and throughout life to main-
tain the cartilaginous regions of the animal including the
articular surfaces. These normal processes depend on the
synthesis and degradation of extracellular matrix proteins
by the chondrocytes. In osteoarthritis there is excessive
degradation of matrix proteins and although initially the
synthesis of proteoglycans and collagens is increased, as
the disease progresses this is insufficient to counteract the
progression cartilage degradation12. Less well established
are the mechanisms by which chondrocytes might internal-
ize unwanted or damaged extracellular matrix components
for degradation within the lysosomal compartments.
Endo180 is an endocytic receptor, being recycled between
clathrin coated pits on the cell surface and the endosomal
apparatus2,3. This trafficking pathway is characteristic of
receptors such as the transferrin and low density lipopro-
tein receptors which bind ligands on the cell surface and
then release them in the low pH intracellular vesicular
environment allowing the receptors to recycle back to the
cell surface. Consequently, we investigated whether
Endo180 functions in postnatal chondrocytes and addition-
ally whether its aberrant expression was found in osteoar-
thritic lesions. For these studies, two inbred strains of mice
were analysed, CBA (normal control) and STR/ort (murine
model of osteoarthritis). Both strains were studied at a
range of ages between 5- and 35-weeks, allowing analysis
of developing (up to approximately 12-weeks) and mature
cartilage. Two key regions were investigated, the tibial
articular cartilage and the epiphyseal growth plate.
In both mouse strains, Endo180 expression is detected
in the superficial, middle and deep zones of the tibial
Fig. 4. Endo180 ligand distribution in articular cartilage. Cryostat sections were cut through the knee joint of a 6-week STR/ort mouse and
probed with (A) purified sEndo180-Fc followed by FITC-anti-human Fc Ig, (B) purified ICAM-Fc followed by FITC-anti-human Fc Ig or (C)
anti-Endo180 antibody followed by FITC-anti-rabbit Ig. AC, articular cartilage; CT, calcified tissue. Original magnification x50.
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articular cartilage in younger animals (aged 6- to 14-
weeks). Articular cartilage chondrocytes are long-lived cells
which in older healthy animals cease to proliferate and exist
within a microenvironment known as the chondron18,19. In
chondrocytes from older animals, expression of Endo180
was found to be markedly reduced. This pattern of receptor
distribution suggests that functionally Endo180 is required
at a time when the articular cartilage matrix is undergoing
active remodeling. In older animals, remodeling has
ceased, turnover of matrix components is much decreased,
and the requirement for endocytosis is probably much less.
STR/ort mice usually develop osteoarthritic lesions on
the medial side of the tibial plateau cartilage13. Such
lesions were readily detectable in 24- to 35-week STR/ort
mice in the present study but comparison of Endo180
expression in damaged cartilage with cartilage from
undamaged regions in matched STR/ort joints, or with age
matched CBA mice, revealed that in mice of this age,
Endo180 expression in the cartilage was low to undetect-
able and was not upregulated in damaged tissue. Given the
observed decrease in receptor expression in normal
chondrocytes after 14-weeks it not surprising that further
changes in Endo180 distribution could not be detected
between normal and osteoarthritic cartilage. It also seems
likely that excessive matrix degradation in osteoarthritic
cartilage increases its permeability so that degradation
products such as cartilage proteoglycan fragments pass
more readily out of it into the synovial fluid20 rather than
being endocytosed by chondrocytes.
An Fc-chimeric molecule incorporating soluble full length
Endo180 ligated to a human Fc tail was produced
(sEndo180-Fc) and used to probe knee joint cryosections
from mice of different ages in both CBA and STR/ort
strains. sEndo180-Fc showed little binding to any regions
within the articular cartilage of any animal at any age and
the use of enzymatic methods to remove extracellular
matrix macromolecules to aid penetration into the cartilage
had no effect on this. The endocytic properties of Endo180
suggest that any target ligands would be rapidly cleared. It
is, therefore, not surprising that very little Endo180 ligand
was detected in young cartilage where there is abundant
receptor expression. However, experiments in our labora-
tory and others have demonstrated that Endo180 is able to
bind to a range of collagens including type II5,6,8 and that
soluble Endo180 constructs can bind to native collagens in
murine kidney sections5. Since type II collagen constitutes
a major component of cartilage matrix, which also contains
several minor collagens21, the failure of sEndo180 to bind
articular cartilage suggests that even after enzyme diges-
tion, these ligand are masked by interactions with other
protein in the tissue.
Endo180 is expressed by chondrocytes in the proliferat-
ing zone of the growth plate. As proliferation continues to
generate new chondrocytes in this zone, preceding popu-
lations of chondrocytes gradually occupy lower positions in
the growth plate until, in the deepest zone, they hypertro-
phy and become calcified. As they move down the growth
plate they modify the surrounding extracellular matrix by
both synthesis and turnover of its proteins22. In contrast to
the positive Endo180 receptor expression, no ligand could
be readily detected in the proliferating zone. Interestingly, in
hypertrophic chondrocytes, Endo180 ligand but no receptor
was detected. It is within the hypertrophic zone that the
process of calcification begins. Collagen II is extensively
Fig. 5. Distribution of Endo180 receptor and Endo180 ligand in the growth plate. For Endo180 receptor staining, cryostat sections through
the knee joints of (A) 5-week male CBA and (B) 6-week old male STR/ort mice were probed with anti-Endo180 antibody followed by
FITC-anti-rabbit Ig. For Endo180 ligand staining, cryostat sections through the knee joint of a (C) 5-week male CBA or (D) 6-week STR/ort
mouse were probed with sEndo180-Fc and detected by FITC-anti-human Fc Ig. Panel E shows a control section of a 6-week STR/ort mouse
probed with FITC-anti-human Fc Ig alone. NHZ, non-hypertrophic zone. HZ, hypertrophic zone. Original magnification ×50.
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degraded in the hypertrophic zone as a result of colla-
genase activity and as matrix is resorbed, hydroxyapatite
mineral and the c-propeptide of type II collagen accumu-
lates in these mineralising sites23. Endo180 ligand(s),
which may include degraded type II collagen6, accumulates
in this zone presumably as a result of lack of Endo180
receptor expression. However, ligand detection by the
sEndo180-Fc probe may also be aided by unmasking
of epitopes as a result of the proteolytic activity in the
hypertrophic zone.
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